Products & ReviewLife Sciences
Ruxolitinib
JAK/STAT pathway inhibitor; Inhibits JAK1 and JAK2
Ruxolitinib
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Ruxolitinib is an ATP mimic that inhibits all Janus-associated kinase (JAK) family kinases with a preference for JAK-1 and JAK-2 over JAK-3 and TYK2 with IC₅₀ values of 3.3, 2.8, 428 and 19 nM respectively (Verstovsek; Quintás-Cardama et al.).
CANCER RESEARCH
- Suppresses erythroid progenitor colony formation from peripheral blood mononuclear cells of polycythemia vera patients with the constitutively active JAK2 V617F mutation. Reduces malignant cell proliferation and decreases interleukin-6 and TNF-α signaling in a JAK2 V617F-driven mouse model of myeloproliferative disorder (Quintás-Cardama et al.).
OTHER
- Promotes hair regrowth in a mouse model of alopecia areata (Xing et al.).
